O
VRTX icon

OrbiMed’s Vertex Pharmaceuticals VRTX Stock Holding History

OrbiMed’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-100,000
Closed -$19.3M – 151
2018
Q3 		$19.3M Sell
100,000
-75,000
-43% -$13.4M 0.23% 91
2018
Q2 		$29.7M Buy
+175,000
New +$27.1M 0.35% 66

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

OrbiMed's VRTX Position: Q3 2025 in Review

OrbiMed sold out of Vertex Pharmaceuticals (VRTX) in Q3 2025, closing a stake of 210,287 shares — an estimated $93.6M sold.

OrbiMed first reported a position in VRTX in Q2 2013 and held it in 49 quarters. The position peaked at $315M in Q3 2017. 1,520 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

  • OrbiMed reported no remaining Vertex Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • OrbiMed sold 210,287 Vertex Pharmaceuticals shares in Q3 2025, an estimated $93.6M.
  • OrbiMed first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 49 quarters.
  • OrbiMed's Vertex Pharmaceuticals position peaked at $315M in Q3 2017.
  • 1,520 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on OrbiMed's 13F filing for Q3 2025, filed 14 Nov 2025.